Story

Danaher Names Diagnostics Chief Julie Sawyer Montgomery as Next CEO

ENTHMSVIIDZHZH-TWJAKOHI
Aug 3, 20262 min read
Danaher Names Diagnostics Chief Julie Sawyer Montgomery as Next CEO
Text size
Background

Danaher (NYSE: DHR) has named company veteran Julie Sawyer Montgomery as its next President and Chief Executive Officer, effective October 1, 2026. The appointment of an internal leader signals a focus on continuity and operational execution, rewarding the architect of the company's high-growth Diagnostics platform.

An Insider With a Strong Record

Sawyer Montgomery, who joined Danaher in 2017 and rose to Executive Vice President, has a quantifiable track record of success within the company. During her leadership of the Diagnostics platform, the division's performance transformed significantly:

  • Revenue grew from approximately $6 billion to nearly $11 billion.
  • Operating profit tripled over the same period.

This growth was achieved in a segment that includes Beckman Coulter Diagnostics, where she served as President starting in 2020. This history of driving both top- and bottom-line growth is central to the board's decision and investor confidence.

Strategic Continuity and M&A

Sample IUX Markets – In-articleAd

The selection also underscores Danaher's commitment to its long-standing M&A strategy. Sawyer Montgomery has direct experience with the company's deal-making playbook, having led the acquisition of Masimo and currently overseeing the pending purchase of StatLab. This experience is critical for a company that relies on bolt-on acquisitions as a core growth driver.

To ensure a seamless transition, Danaher confirmed there would be no change to its third-quarter or full-year 2026 financial guidance. Outgoing CEO Rainer Blair will also remain with the company as a senior advisor through March 31, 2027, providing an extended handover period.

Market Perspective

For investors, the appointment represents a bet that Sawyer Montgomery can scale the operational playbook she successfully deployed in the Diagnostics segment across Danaher's entire portfolio. Her proven ability to expand revenue and profitability is the key bull case for her leadership.

However, the primary challenge will be the significant step up in complexity from managing a single platform to steering the entire global enterprise. The market will be watching closely to see how her operational expertise translates to the broader and more diverse responsibilities of the CEO role.

Read next

More on Stocks
Back to latest news

LATEST